ERLOTINIB-BEVACIZUMAB FOR NSCLC

Eur Respir J. 2015 Mar 18. pii: ERJ-02290-2014. [Epub ahead of print]

Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.

Thomas M1, Fischer J2, Andreas S3, Kortsik C4, Grah C5, Serke M6, von Eiff M7, Witt C8, Kollmeier J9, Müller E10, Schenk M11, Schröder M12, Villalobos M13, Reinmuth N14, Penzel R15, Schnabel P15, Acker T16, Reuss A16, Wolf M;  on behalf of the ABC-Lung Cancer Group.

Author information

Abstract

Erlotinib with bevacizumab showed promising activity in recurrent nonsquamous (NS) nonsmall cell lung cancer (NSCLC). The INNOVATIONS study was designed to assess in first-line treatment of unselected cisplatin-eligible patients this combination compared to cisplatin, gemcitabine and bevacizumab. Stage IIIB/IV patients with NS-NSCLC were randomised on erlotinib (150 mg daily) and bevacizumab (15 mg·kg-1 on day 1, every 3 weeks) (EB) until progression, or cisplatin (80 mg·m-2 on day 1, every 3 weeks) and gemcitabine (1250 mg·m-2 on days 1 and 8, every 3 weeks) up to six cycles and bevacizumab (15 mg·kg-1 on day 1, every 3 weeks) (PGB) until progression. 224 patients were randomised (EB n=111, PGB n=113). The response rate (12% versus 36%; p<0 .0001="" 1.01-1.97="" 1.39-2.45="" 1.41="" 1.85="" 12.6="" 17.8="" 3.5="" 6.9="" 95="" abstracttext="" and="" approaches="" appropriate="" care="" chemotherapy="" ci="" clearly="" combination="" eb.="" epidermal="" factor="" favoured="" first-line="" growth="" hazard="" hr="" in="" mandate="" median="" molecular="" months="" mutations="" n="32)," not="" ns-nsclc.="" of="" overall="" p="0.04)" patient="" patients="" pgb.="" platinum-based="" progression-free="" rate="" ratio="" receptor="" remains="" response="" selection.="" standard="" strongly="" superior="" survival="" targeted="" testing="" the="" treatment="" unselected="" versus="" were="" with="">